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Step 2: To a vial containing 2,6-dimethyl-4-((4-nitrophenyl) sulfonyl)morpholine (0.21 g, 0. 69 mmol) was added CH 3 OH:CH 2 Cl 2 (4 mL:2 mL) and the reaction vessel was cooled to 0 °C. Raney nickel (0.004 g, 0. 069 mmol) was added followed by portionwise addition of sodium borohydride (0.052 g, 1.39 mmol) . The reaction stirred at 0 °C for 30 minutes and was then diluted with CH 2 Cl 2 (10 mL) and filtered slowly. The CH 2 Cl 2 layer was washed with water (10 mL), dried with MgSO 4 , filtered, adsorbed to silica and purified by silica gel flash column chromotography (15 min, 0 -5 % v/v CH 3 OH/CH 2 Cl 2 ) to produce 4-((2,6-dimethylmorpholino)sulfonyl)aniline (0.18 g, 0.68 mmol, 98 % yield) . 1 H NMR (400 MHz, CDCl 3 ) δ 7.50 (d, J = 8.7 Hz, 2H), 6.69 (d, J = 8.7 Hz, 2H), 4.19 (s, 2H), 3.73 -3.63 (m, 2H), 3.56 -3.46 (m, 2H), 1.92 (dd, J = 11.4, 10.2 Hz, 2H), 1.12 (d, J = 6.3 Hz, 6H) .
Step 3: To a microwave vial was added 4-((2,6-dimethylmorpholino)sulfonyl)aniline (0.15 g, 0. 62 mmol), 5-nitro-2-furoyl chloride (0.12 g, 0. 69 mmol) and acetonitrile (3 mL) . The vial was sealed and heated to 150 °C in a microwave reactor for 20 minutes. The reaction then cooled to room temperature and was diluted with CH 2 Cl 2 (10 mL) and washed with saturated NaHCO 3 (10 mL). The CH 2 Cl 2 layer was collected, dried with MgSO 4 , filtered and adsorbed to silica gel. The crude product was purified by silica gel flash column chromotography (0) (1) (2) (3) (4) (5) OH/CH 2 Cl 2 ) to produce 7 (0.14 g, 0.38 mmol, 60 % yield) as a white solid. 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.02 (s, 1H), 8.04 (d, J = 8.8 Hz, 2H), 7.85 (d, J = 3.9 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 3.9 Hz, 1H), 3.70 -3.56 (m, 2H), 3.55 -3.47 (m, 2H), 1.91 -1.73 (m, 2H), 1.06 (d, J = 6.2 Hz, 6H).
13 C NMR (100 MHz, DMSO-d 6 ): δ 155. 0, 152.0, 147.3, 142.3, 129.6, 128.9, 120.4, 117.3, 113.4, 70.6, 50.6, 18.5 
N-(4-(Piperazin-1-ylsulfonyl)phenyl)-5-nitrofuran-2-carboxamide (8). Prepared as described for compound 7,
Step 1, except using 4-nitrobenzenesulfonyl chloride (0.56 g, 2.50 mmol), pyridine (0.30 mL, 3 .70 mmol), 4-N-Bocpiperizine (0.51 g, 2.80 mmol) and THF (1.5 mL) to produce tert-butyl 4-((4-nitrophenyl)sulfonyl)piperizine-1-carboxylate (0.35 g, 0.94 mmol, 38 % yield 3.46 -3.36 (m, 4H) , 2.96 (t, J = 5.1 Hz, 4H), 1.35 (s, 9H) . The tert-butyl 4-((4-nitrophenyl)sulfonyl) piperizine-1-carboxylate was then treated as for described for compound 7, Step 2, sulfonyl)piperizine-1-carboxylate (0.14 g, 0.36 mmol) in CH 3 OH:CH 2 Cl 2 (3 mL:1 mL) with Raney nickel (0.002 g, 0. 036 mmol) and sodium borohydride (0.028 g, 0. 73 mmol) was used to produce tert-butyl 4-((4-aminophenyl)sulfonyl)piperazine-1-carboxylate (0.12 g, 0.037 mmol, 96 % yield) . 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.35 (d, J = 8.7 Hz, 2H), 6.65 (d, J = 8.8 Hz, 2H), 6.12 (s, 2H), 3.37 (d, J = 5.3 Hz, 4H), 2.75 (t, J = 5.1 Hz, 4H), 1.35 (s, 9H) . As described for compound 7, Step 3, sulfonyl) piperazine-1-carboxylate (0.23 g, 0. 82 mmol), 5-nitro-2-furoyl chloride (0.16 g, 0. 90 mmol) and acetonitrile (3 mL) was used to produce 8 (0.11 g, 0. 26 mmol, 31 % yield) as a yellow solid. The BOC group was advantageously removed under these same conditions and did not require further manipulation. 13 C NMR (100 MHz, DMSO-d 6 ): δ 155. 0, 151.9, 147.3, 142.1, 129.8, 128.8, 120.4, 117.3, 113.4, 46.6, 44.5 
N-(4-((4-Hydroxypiperidin-1-yl)sulfonyl)phenyl)-5-nitrofuran-2-carboxamide (9). Prepared as described for compound 7,
Step 1, except 4-nitrobenzenesulfonyl chloride (0.28 g, 1.27 mmol), triethylamine (0.26 mL, 1.91 mmol), 4-hydroxypiperidine (0.14 g, 1.40 mmol) in CH 2 Cl 2 (4 mL) was stirred at rt to produce 1-((4-nitrophenyl)sulfonyl)piperidin-4-ol (0.32 g, 1.11 mmol, 88 % yield 1.53 -1.36 (m, 2H) . sulfonyl)piperidin-4-ol was then treated as described for compound
7,
Step 2, except 1-((4-nitrophenyl)sulfonyl)piperidin-4-ol (0.15 g, 0. 54 mmol) in CH 3 OH:CH 2 Cl 2 (3 mL:1 mL) with Raney nickel (0.003 g, 0.053 mmol) and sodium borohydride (0.041 g, 1.07 mmol) was used to produce 1-((4-aminophenyl)sulfonyl)piperidin-4-ol (0.074 g, 0.29 mmol, 54 % yield 1.49 -1.29 (m, 2H) . As described for compound 7, Step 3, sulfonyl)piperidin-4-ol (0.074 g, 0.29 mmol) was treated with 5-nitro-2-furoyl chloride (0.056 g, 0.32 mmol) and acetonitrile (2 mL) to produce 9 (0.058 g, 0.15 mmol, 51 % yield) as a white solid. 1 0, 151.9, 147.3, 142.0, 130.6, 128.6, 120.3, 117.2, 113.4, 63.8, 43.2, 32.9 N-(4-(Piperidin-1-ylsulfonyl)phenyl)-5-nitrofuran-2-carboxamide (10). Prepared as described for compound 3, except commercially available 4-(piperidin-1-ylsulfonyl)aniline (0.13 g, 0. 53 mmol), 5-nitro-2-furoyl chloride (0.10 g, 0.580 mmol) and acetonitrile (3 mL) was used to produce 10 (0.17 g, 0.44 mmol, 82 % yield) as a white solid. 0, 152.0, 147.3, 142.0, 130.5, 128.6, 120.4, 117.3, 113.4, 46.6, 24.7, 22.9 Fluoropiperidin-1-yl) sulfonyl)phenyl)-5-nitrofuran-2-carboxamide (11). Step 1, sulfonyl)piperidine: To a vial was added 4-nitrobenzenesulfonyl chloride (0.13 g, 0.58 mmol), triethylamine (0.20 mL g, 1.5 mmol), 4-fluoropiperidine hydrochloride (0.097 g, 0.70 mmol) and CH 2 Cl 2 (2 mL).
N-(4-((4-
The reaction was stirred at rt for 18 h and was then diluted with saturated NaHCO 3 (5 mL). The aqueous layer was extracted with CH 2 Cl 2 (3 x 8 mL) and the organic layers were combined then dried with MgSO 4 . The crude product was adsorbed to silica and purified by silica gel flash chromatography (0 -35% EtOAc:hexanes) to produce 4-fluoro-1-((4-nitrophenyl)sulfonyl)piperidine (0.15 g, 0.52 mmol, 89 % yield 1, 152.0, 147.4, 142.4, 130.2, 128.7, 120.5, 117.3, 113.4, 86.8 (d, J = 163.5 
N-(4-((4-chloropiperidin-1-yl)sulfonyl)phenyl)-5-nitrofuran-2-carboxamide (12).
Step 1: To a vial was added 4-nitrobenzenesulfonyl chloride (0.32 g, 1.4 mmol), pyridine (0.12 mL, 1.4 mmol) and THF (1.5 mL). The reaction was stirred at room temperature while 4-chloropiperidine (0.13 g, 1.0 mmol) was added dropwise over 10 minutes. The reaction was subsequently heated to 60 °C for 20 minutes then allowed to cool to room temperature, was diluted with EtOAc (10 mL) and washed with saturated NaHCO 3 (10 mL). The EtOAc extract was separated, dried with MgSO 4 , filtered and adsorbed to silica and purified by silica gel flash column chromotography (15 min, 0 -30% v/v EtOAc/hexanes) to produce 4-chloro-1-((4-nitrophenyl)sulfonyl)piperidine (0.29 g, 0.96 mmol, 96 % yield Step 2: To a vial containing 4-chloro-1-((4-nitrophenyl)sulfonyl)piperidine (0.29 g, 0.96 mmol) was added CH 3 OH:CH 2 Cl 2 (3 mL:3 mL) and the reaction was cooled to 0 °C. The Raney nickel (0.006 g, 0.096 mmol) was added followed by portionwise addition of sodium borohydride (0.073 g, 1.9 mmol). The reaction was stirred at 0 °C for 30 minutes and was then diluted with CH 2 Cl 2 (10 mL) and filtered slowly. The CH 2 Cl 2 layer was washed with water (10 mL), dried with MgSO 4 , filtered, adsorbed to silica and purified by silica gel flash column chromotography (15 min, 0 -5 % v/v CH 3 OH/CH 2 Cl 2 ) to produce 4-((4-chloropiperidin-1-yl)sulfonyl)aniline (0.23 g, 0. 82 mmol, 86 % yield).
(d, J = 3.9 Hz, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 3.9 Hz, 1H), 4.27 (m, 1H), 3.17 (m, 2H) , 2.87 (m, 2H), 2.10 (m, 2H), 1.79 (m, 2H).
13 C NMR (100 MHz, DMSO-d 6 ): δ 154. 9, 151.9, 147.3, 142.2, 130.4, 128.6, 120.4, 117.2, 113.4, 56.1, 43.4, 33. 0, 151.9, 147.3, 142.0, 130.6, 128.6, 120.4, 117.3, 113.4, 46.1, 32.8, 29.3, 21.3 Step 2, 4,4-dimethyl-1-((4-nitrophenyl)sulfonyl)piperidine (0.12 g, 0.40 mmol) in CH 3 OH:CH 2 Cl 2 (3 mL:1 mL) was treated with Raney nickel (0.002 g, 0.040 mmol) and sodium borohydride (0.030 g, 0. 80 mmol) to produce 4-((4,4-dimethylpiperidin-1-yl)sulfonyl)aniline (0.11 g, 0.39 mmol, 98 % yield Step 3, 0, 151.9, 147.3, 141.9, 130.8, 128.5, 120.3, 117.2, 113.4, 42.3, 37.1, 27.8 N-(4-((4-Tert-butylpiperidin-1-yl)sulfonyl)phenyl)-5-nitrofuran-2-carboxamide (15). Prepared as described for compound 7, Step 1, 0. 91 mmol), pyridine (0.22 mL, 2.72 mmol), 4-tert-butylpiperidine hydrochloride (0.16 g, 0. 91 mmol) and THF (10 mL) was used to produce 4-(tert-butyl)-1-((4-nitrophenyl)sulfonyl)piperidine (0.088 g, 0.27 mmol, 30 % yield 0, 152.0, 147.3, 142.0, 130.5, 128.7, 120.3, 117.3, 113.4, 54.9, 46.8, 44.8, 31.8, 27.0, 25.7 152.0, 147.3, 142.0, 130.6, 128.7, 120.4, 117.3, 113.4, 41.6, 35.2, 34.7, 30.0, 26.1, 20.8 0, 152.0, 147.3, 142.0, 131.3, 128.5, 120.4, 117.3, 113.4, 47.8, 24.7 
N-(4-(Phenylsulfonyl)phenyl)-5-nitrofuran-2-carboxamide (18).
Prepared as described for compound 3, commercially available 4-(phenylsulfonyl)aniline (0.087 g, 0.37 mmol), 5-nitro-2-furoyl chloride (0.072 g, 0.41 mmol) and acetonitrile (2 mL) was used to produce 18 (0.085 g, 0.23 mmol, 61 % yield) as a white solid.
1 H NMR (400 MHz, DMSO-d 6 ) δ 11.00 (s, 1H), 8.00 (s, 4H), 7.98 -7.93 (m, 2H), 7.83 (d, J = 3.9 Hz, 1H), 7.73 -7.67 (m, 2H), 7.67 -7.58 (m, 2H).
13 H NMR (125 MHz, DMSO-d 6 ): δ 155. 0, 151.9, 147.2, 142.6, 141.5, 135.9, 133.6, 129.7, 128.7, 127.1, 120.7, 117.4, 113.4 
N-(4-((Tetrahydro-2H-pyran-4-yl)sulfonyl)phenyl)-5-nitrofuran-2-carboxamide (19).

4-((4-Nitrophenyl)thio)tetrahydro-2H-pyran,
Step 1: To a vial was added the 4-bromotetrahydropyran (0.10 mL, 0.91 mmol), 4-nitrothiophenol (0.17 g, 1.0 mmol), cesium carbonate (0.49 g, 1.5 mmol) and acetonitrile (5 mL). The reaction was then heated to 50 °C for 4 h then was allowed to cool to rt and was quenched with saturated NaHCO 3 (7 mL). The reaction was extracted with EtOAc (3 x 10 mL). The organic layers were combined and dried with MgSO 4 , filtered and adsorbed to silica then purified by silica gel flash chromatography (0 -35% EtOAc:hexanes) to produce 4-((4-nitrophenyl)thio)tetrahydro-2H-pyran (0.15 g, 0.63 mmol, 69 %). 4-((4-nitrophenyl) sulfonyl)tetrahydro-2H-pyran, Step 2: To a vial was added 4-((4-nitrophenyl)thio)tetrahydro-2H-pyran (0.15 g, 0.63 mmol) and acetic acid (5 mL). A solution of 30% w/v hydrogen peroxide in water (0.22 mL, 1.94 mmol) was then slowly added to the reaction at rt and the reaction was heated to 50 °C for 5 h. The reaction was allowed to cool to rt and was extracted with CH 2 Cl 2 (3 x 10 mL). The combined organic layers were washed with water (30 mL), dried with MgSO 4 , filtered and concentrated to provide 4-((4-nitrophenyl) sulfonyl)tetrahydro-2H-pyran (0.16 g, 0.58 mmol, 92 %).
1 H NMR (400 MHz, CDCl 3 ) δ 8.43 (d, J = 8.8 Hz, 2H), 8.10 (d, J = 8.9 Hz, 2H), 4.12 -4.03 (m, 2H), 3.34 (td, J = 11.8, 2.4 Hz, 2H), 3.20 (tt, J = 11.9, 4.1 Hz, 1H), 1.95 -1.74 (m, 4H) . Synthesis of 4-((tetrahydro-2H-pyran-4-yl) sulfonyl)aniline, Step 3 -as described for compound 7, (4-((tetrahydro-2H-pyran-4-yl) 
Step 4 -as described for compound 7, Step 3: 4-((tetrahydro-2H-pyran-4-yl)sulfonyl)aniline (0.13 g, 0.52 mmol), 5-nitro-2-furoyl chloride (0.10 g, 0.58 mmol) and acetonitrile (3 mL) was used to produce 19 (0.010 g, 0.026 mmol, 1 % yield) as a white solid. 1 1, 152.0, 147.2, 142.9, 131.3, 130.0, 120.4, 117.4, 113.4, 65.4, 58.8, 25.3 
N-(4-(cyclohexylsulfonyl)phenyl)-5-nitrofuran-2-carboxamide (20).
Synthesis of cyclohexyl (4-nitrophenyl) sulfane, Step 1: Cyclohexyl(4-nitrophenyl)sulfane was prepared using a procedure adapted from Hayashi et al. 1 To a vial was added cyclohexyl mercaptan (0.14 mL, 1.13 mmol) and DMF (5 mL). The 60% w/w sodium hydride (0.045 g, 1.13 mmol) was added to the reaction portionwise over 3 minutes. After the addition the reaction was stirred at rt for 10 minutes then 4-iodo-nitrobenzene (0.31 g, 1.2 mmol) was added. The reaction was then heated to 70 °C and stirred for 4 hours then allowed to cool to rt and was quenched slowly with 1.0 M aqueous HCl to pH 3. The aqueous layer was then extracted with EtOAc (3 x 10 mL) and the organic layers were combined and washed with water (3 x 30 mL). The organic layers were then dried with MgSO 4 , filtered and adsorbed to silica then purified by silica gel flash chromatography (0 -10% EtOAc:hexanes) to produce cyclohexyl(4-nitrophenyl)sulfane (0.26 g, 1.1 mmol, 96 %). 
Step 2: To a vial was added cyclohexyl(4-nitrophenyl)sulfane (0.26 g, 1.1 mmol) and acetic acid (5 mL). A solution of 30% w/v hydrogen peroxide in water (0.38 mL, 3.4 mmol) was then slowly added to the reaction at rt and the reaction was heated to 50 °C for 5 h. The reaction was allowed to cool to rt and was extracted with CH 2 Cl 2 (3 x 10 mL). The combined organic layers were washed with water (30 mL), dried with MgSO 4 , filtered and concentrated to provide 1-(cyclohexylsulfonyl)-4-nitrobenzene (0.37 g, 0.105 mmol, 98%). 
Synthesis of N-(4-(cyclohexylsulfonyl)phenyl)-5-nitrofuran-2-carboxamide (20), Step 4 -as described for compound
7,
Step 3: 4-(cyclohexylsulfonyl)aniline (0.15 g, 0.62 mmol), 5-nitro-2-furoyl chloride (0.12 g, 0.69 mmol) and acetonitrile (3 mL) was used to produce 20 (0.14 g, 0.38 mmol, 60 % yield) as a white solid.
1 H NMR (400 MHz, 0, 151.9, 147.3, 142.7, 131.9, 129.8, 120.3, 117.3, 113.4, 61.7, 39.5, 25.1, 24.7, 24.3 8, 153.8, 145.4, 142.4, 130.1, 129.4, 129.1, 128.9, 120.3, 65.3, 54.9, 45.9 4, 143.3, 139.3, 132.8, 130.0, 128.9, 128.4, 128.2, 119.9, 65.3, 45.9 2, 143.7, 134.4, 132.0, 128.8, 128.5, 128.4, 127.9, 119.9, 65.3, 45.9 2, 144.3, 140.7, 129.4, 128.8, 128.4, 123.6, 120.4, 65.3, 45.9 0, 147.8, 142.8, 135.8, 134.4, 130.32, 130.30, 128.5, 126.6, 122.6, 120.2, 42.3, 37.1, 27.8 
N-(4-((4,4-Dimethylpiperidin-1-yl)sulfonyl)phenyl)-1-methyl-5-nitro-1H-imidazole-2-carboxamide (26).
To a vial was added 4-((4,4-dimethylpiperidin-1-yl)sulfonyl)aniline (0.043 g, 0.16 mmol) -used in the preparation of 14.
The vial was evacuated with argon 3 times and then anhydrous THF (0.5 mL) was added. Then 2.0 M trimethylaluminum (0.080 mL, 0.16 mmol) in toluene was added and the reaction stirred at 40 °C for 1 h. A solution of ethyl 1-methyl-5-nitro-1H-imidazole-2-carboxylate (0.021 g, 0.11 mmol) in anhydrous THF (1.5 mL) was added and the reaction stirred at reflux for 3 h. The mixture was cooled to rt and with 1.0 M HCl was added dropwise (10 mL), followed by extraction with CH 2 Cl 2 (3 x 10 mL). The organic layers were dried with MgSO 4 , filtered and adsorbed to silica and purified by silica gel flash chromatography (0 -5% v/v CH 3 OH/CH 2 Cl 2 ). The fractions containing the product were not fully pure, it was re-adsorbed to silica and purified by silica gel flash chromatography (0 -45 % EtOAc:hexanes) to produce 26 (0.014 g, 0.033 mmol, 31 % yield 
N-(4-(Morpholinosulfonyl)phenyl)-5-methylfuran-2-carboxamide (28). Prepared as described for compound 3,
commercially available 4-(morpholinosulfonyl)aniline (0.13 g, 0.52 mmol), 5-methyl-2-furoyl chloride (0.090 g, 0.62 mmol) and acetonitrile (2 mL) used to produce 28 (0.083 g, 0.24 mmol, 46 % yield) as a white solid. 
N-(4-(Morpholinosulfonyl)phenyl)-5-bromofuran-2-carboxamide (29).
Purchased from Chembridge Corporation. 1 
Cellular Assay Protocols High Throughput Screening (HTS)
HTS was performed with a previously described luminescent Chinese Hamster Ovary (CHO-K1) reporter assay piqued to identify small molecules that splice XBP1 or activate CHOP. 1 The assay was scaled-down to a 1536 well format using 500 CHO-CHOP-luc or CHO-XBP1-luc cells in plated in 5 µL F12 plus Glutamax medium supplemented with non-essential amino acids (NEAA) (Invitrogen, Grand Island, NY). When treated with 2.5 µg/ml tunicamycin both cell lines yielded a 6 fold increase in luciferase that consistently produced Z' values > 0.64. The progenitor of compound "12" was identified from the HIN Molecular Libraries Small Molecule Repository of >350,000 compounds, all of which were tested at 10 µM. HTS screening was performed at the Conrad Prebys Center for Chemical Genomics at the Sanform|Burnham Medical Research Institute in La Jolla, CA.
Cell lines and proliferation assays
Murine embryonic fibroblasts (MEF) were cultured in Dulbecco's Modified Eagle Medium and supplemented with penicillin-streptomycin, 10% Fetal Bovine serum, and NEAA . Luminescent proliferation assays were performed with 30 µL of CellTiter-Glo® (Promega) added to each well at the indicated time points; luminescence was measured after a 10 minute incubation. Proliferation assays were performed at least three times in triplicate 96-well plates (50 µL final volume) using 7500 cells/well. Oral squamous cell carcinoma proliferation assays were performed similarly using 12,500 cells. Error bars represent standard deviation of technical replicates for all proliferation assays.
PCR analysis
One microgram of Trizol (Invitrogen) harvested RNA was used for reverse transcription. cDNA pools generated with random hexamers were used for RT-PCR analysis of XBP1 using a single human-specific pair of primers that produces amplicons for un-spliced (XBP1u) and spliced (XBP1s). The forward primer was CCT TGT AGT TGA GAA CCA GG, and the reverse primer was GGG GCT TGG TAT ATA TGT GG. 2 For quantitative RT-PCR (qRT-PCR), total RNA was harvested with a Cells-to-CT™ Kit (Ambion) in 96 well plates. RNA's were reverse transcribed using random hexamers and amplified using SsoFast probes Supermix (Bio-Rad) and TaqMan (Life Technologies) primer probes, as previously described.
3 18s ribosomal RNA was used as for internal control and the fold changes were calculated with the delta delta CT method; error bars represent standard deviation of technical replicates. The Life Technologies primer/probe pairs were as follows:
In vitro pharmacology assay protocols Aqueous Solubility Protocol -Compound solubility in aqueous solution was measured using an automated kinetic solubility method at the Sanford Burnham Medical Research Institute. The concentration of the compound in a saturated pH-buffered aqueous solution was determined by UV absorbance (250-498 nm) and compared to the spectra of a precipitation-free reference solution. Aqueous solubility was measured in phosphate buffered saline (PBS) at room temperature (23°C). PBS by definition is 137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate monobasic and a pH of 7.4.
Plasma Stability -Stability of the compound in human plasma and mouse plasma (BioChemed Services) was determined. All liquid dispense and transfer steps were performed with the Freedom Evo automated liquid handler (Tecan US). Plasma was allowed to thaw at room temperature prior to preparing the assay solution of plasma:1X PBS (1:1). The assay solution was warmed up at 37 °C prior of adding the compound. Immediately after compounds were added, time 0 min aliquots were promptly collected and mixed with cold acetonitrile (spiked with an internal standard). The remainder of the reaction volume was incubated at 37 °C with shaking. Additional aliquots were collected 180 min after the start of the reaction and promptly quenched with cold acetonitrile (spiked with an internal standard). Samples were centrifuged at 3000 rpm for 10 min. The amount of compound in the supernatant was determined by LC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap) and the percent of parent compound remaining after 180 min was calculated by the following formula:
Results reported are the mean of each reaction duplicate, normalized to the internal standard, and expressed as a percent of compound remaining after the incubation time.
Assay details:
• Mouse Plasma in K3 EDTA • Procaine and Procainamide were used as standards. Procaine is highly unstable, Procainamide is highly stable.
• Assay concentrations of standards and test compound: 1 µM • Incubation Time: 3 hrs • Reaction pH: 7.4
• Assay DMSO final concentration: 2.5% Plasma Protein Binding -Teflon® Base Plate wells were rinsed with 20% ethanol for 10 minutes. Ethanol was then removed and wells were rinsed with ultrapure water and allowed to dry. RED (rapid equilibrium dialysis) inserts from Thermo Scientific (Pierce) were placed (open end up) into the wells of the base plate. All liquid dispense and transfer steps were performed with the Freedom Evo automated liquid handler (Tecan US). The sample chambers (red ring) contained 300 µl of a mixture of plasma and compound, and the buffer chambers received 500 µl of dialysis buffer (1X PBS, pH7.4). Duplicate inserts were made for each concentration tested. The base plate was covered with sealing tape and incubated at 37˚C on an orbital shaker at 350 rpm for 4 hours. After the incubation time, equal volume from both chambers were removed and transferred to a 96 well plate containing either plasma or buffer. To precipitate proteins and release compounds, ice cold acetonitrile (with an internal standard) was added. Samples were vortexed and centrifuged at 3700 rpm for 10 min. The amount of compound in the supernatant was determined by LC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap). The percent of free and bound compounds were calculated with the following formula:
% of bound parent amount of compound in donor -receiver compound = amount of compound in donor
Results reported are the mean of each reaction duplicate, normalized to the internal standard, and expressed as a percent compound bound after the incubation time. Hepatic Microsome Stability -Metabolic stability was assessed in the presence of mouse liver mirosomes (XenoTech, P/N M1000). All liquid dispense and transfer steps were performed with the Freedom Evo automated liquid handler (Tecan US). NADPH, a required cofactor for CYP450 metabolism, was provided by the NADPH Regenerating System, Solutions A (BD Biosciences, P/N 451220) and B (BD Biosciences, P/N 451200). Compound stock solutions were initially prepared in 100% DMSO and subsequently diluted in acetonitrile for the assay. The pH of the reactions was kept at ~ 7.4 with potassium phosphate buffer (BD Biosciences, P/N 451201). The reactions were started after adding NADPH to the reaction plate containing microsomes and compounds and time 0 min aliquots were promptly collected and mixed with ice cold acetonitrile (spiked with internal standards) to quench the reactions. The remainder of the reaction volume was incubated at 37 °C with shaking. Additional aliquots were collected 60 min after the start of the reaction and promptly quenched with ice cold acetonitrile (spiked with an internal standard). Samples were centrifuged at 3000 rpm for 10 min. The amount of compound in the supernatant was determined by LC/MS/MS (Applied Biosystems, Sciex API4000 Q-Trap) and the percent of parent compound remaining after 60 min was calculated by the following formula:
All reactions were run in triplicate, except negative controls (no NADPH) which were performed as single reactions. Results reported are the mean of each reaction triplicate, normalized to the internal standard, and Human Hepatocyte Cytotoxicity -Immortalized human hepatocytes, Fa2N-4 cells (XenoTech, P/N IFH15), were resuspended in MFE Plating medium (XenoTech), seeded in collagen-coated plates (VWR) at ~50,000 cells/well, and incubated in a humidified CO2 incubator at 37 ⁰C. After 4 hrs, the medium was replaced with MFE Support medium (XenoTech). On the third day, the cells were incubated with a range of concentrations (0.01-50 µM) of the test compound. After 24 hrs, cell viability was determined by cellular ATP levels using the Luminescence ATP Detection Assay System (ATPlite 1 step, Perkin Elmer) and the Infinite M200 plate reader (Tecan). 
